Cite
Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO.
MLA
Menninger, Loredana, et al. “Membrane Oxygenator Longevity Was Higher in Argatroban‐treated Patients Undergoing VvECMO.” European Journal of Clinical Investigation, vol. 53, no. 6, June 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1111/eci.13963.
APA
Menninger, L., Körner, A., Mirakaj, V., Heck, S. K., Haeberle, H. A., Althaus, K., Baumgaertner, M., Jost, W., Schlensak, C., Rosenberger, P., & Koeppen, M. (2023). Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO. European Journal of Clinical Investigation, 53(6), 1–11. https://doi.org/10.1111/eci.13963
Chicago
Menninger, Loredana, Andreas Körner, Valbona Mirakaj, Swain, Ka‐Lin Heck, Helene A. Haeberle, Karina Althaus, Michael Baumgaertner, et al. 2023. “Membrane Oxygenator Longevity Was Higher in Argatroban‐treated Patients Undergoing VvECMO.” European Journal of Clinical Investigation 53 (6): 1–11. doi:10.1111/eci.13963.